Phillip Md Et Al Frost Purchases 40,000 Shares of Cocrystal Pharma (NASDAQ:COCP) Stock

Cocrystal Pharma, Inc. (NASDAQ:COCP) Director Phillip Md Et Al Frost acquired 40,000 shares of the company’s stock in a transaction on Friday, December 26th. The stock was acquired at an average cost of $0.97 per share, with a total value of $38,800.00. Following the completion of the purchase, the director directly owned 1,768,551 shares in the company, valued at approximately $1,715,494.47. This represents a 2.31% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Wednesday, December 24th, Phillip Md Et Al Frost bought 25,000 shares of Cocrystal Pharma stock. The shares were acquired at an average price of $0.97 per share, for a total transaction of $24,250.00.
• On Wednesday, November 26th, Phillip Md Et Al Frost purchased 4,000 shares of Cocrystal Pharma stock. The stock was acquired at an average cost of $0.99 per share, with a total value of $3,960.00.
• On Tuesday, November 25th, Phillip Md Et Al Frost purchased 20,000 shares of Cocrystal Pharma stock. The stock was bought at an average price of $0.94 per share, with a total value of $18,800.00.

Cocrystal Pharma Price Performance

Shares of NASDAQ COCP opened at $0.95 on Wednesday. Cocrystal Pharma, Inc. has a 1-year low of $0.90 and a 1-year high of $2.67. The business’s 50 day moving average is $1.03 and its two-hundred day moving average is $1.32. The stock has a market capitalization of $13.07 million, a P/E ratio of -1.01 and a beta of 1.05.

Cocrystal Pharma (NASDAQ:COCP) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.03. As a group, equities research analysts anticipate that Cocrystal Pharma, Inc. will post -1.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cocrystal Pharma in a research report on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $6.00.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.